Can fecal microbiota transplantation treat ulcerative colitis?

How well does FMT actually work for ulcerative colitis?

FMT is significantly more effective than placebo or standard therapy for inducing remission in active UC, but the effect is moderate — not a cure-all. A 2023 meta-analysis of 13 randomized controlled trials (580 patients) found that FMT led to clinical remission in about 42% of patients versus 23% in control groups — roughly a 73% higher chance of remission [3]. In individual trials, the numbers vary: one large trial combining FMT with an anti-inflammatory diet achieved clinical response in 66% of patients (23 out of 35) compared to 36% (11 out of 31) with optimized standard medical therapy [2]. Another trial using oral FMT capsules after antibiotics found 53% (8 of 15) achieved corticosteroid-free remission with endoscopic improvement, versus 15% (3 of 20) on placebo [6]. A capsulized FMT study reported clinical remission in 57% (12 of 21) of patients [13]. These figures consistently show FMT outperforms placebo, but roughly half of patients do not respond.

Importantly, FMT appears as effective as standard treatments like glucocorticoids, but with fewer side effects. A 2022 prospective study directly compared FMT to glucocorticoids for inducing remission in mild-to-moderate UC: 55% of FMT patients (34 of 62) achieved clinical and endoscopic remission at 12 weeks, versus 48% of glucocorticoid patients (29 of 60) — a difference that was not statistically significant, meaning FMT was roughly equivalent [4]. However, adverse events were far more common with glucocorticoids (58% of patients) than with FMT (23%), and two serious adverse events occurred only in the glucocorticoid group [4]. This suggests FMT may be a safer alternative for induction therapy.

What makes FMT more or less likely to work?

The way FMT is delivered makes a big difference. A 2026 randomized pilot trial (STOP-Colitis) directly compared delivery routes: colonic FMT (via colonoscopy plus enemas) achieved a 75% clinical response rate (9 of 12 patients), while nasogastric (tube to the stomach) FMT achieved only 25% (2 of 8) [1]. A meta-analysis of 7 studies confirmed this pattern: FMT given via colonoscopy was significantly more effective than placebo for inducing remission (odds ratio 4.06), whereas upper gastrointestinal delivery showed no benefit over placebo [12]. The STOP-Colitis trial also found that response depended on successful microbial engraftment — the donor bacteria actually taking up residence in the patient's gut — which led to increased fecal microbial diversity and more short-chain fatty acid-producing bacteria [1]. This microbial shift was linked to an anti-inflammatory immune response: responders had a significant increase in regulatory T cells and a decrease in pro-inflammatory Th17 and CD8+ T cells [1].

Multiple doses over time also matter more than a single treatment. A 2023 randomized trial testing a single-dose FMT for maintaining remission in quiescent UC found no benefit: 54% of FMT patients (13 of 24) stayed in remission over 12 months versus 41% of placebo (10 of 24), a difference that was not statistically significant [7]. In contrast, studies using multiple doses — such as weekly colonoscopic infusions for 7 weeks [2], or daily oral capsules for 12 weeks [11] — showed better results. For patients with recurrent C. difficile infection plus UC, repeat FMT was significantly more effective than a single FMT (84% vs 50% cure rate) [5]. The LOTUS trial found that continuing oral FMT capsules for 48 weeks after initial response maintained remission in all 4 patients who continued, while all 6 who stopped relapsed [6].

Patient selection also matters. A 2025 pilot study of FMT enemas for resistant ulcerative proctitis (a hard-to-treat form of UC limited to the rectum) found that patients with lower baseline disease activity were more likely to respond: higher Mayo score (odds ratio 0.28) and higher fecal calprotectin (odds ratio 0.66) predicted failure [8]. This suggests FMT works best in milder or earlier disease, not in severe, treatment-resistant cases.

Is FMT safe, and what are the remaining challenges?

FMT appears generally safe for UC patients, with side effects mostly mild and temporary. The 2023 meta-analysis found no significant difference in adverse event rates between FMT and control groups (risk ratio 1.00) [3]. In the FMT-vs-glucocorticoids study, only 23% of FMT patients had adverse events versus 58% on glucocorticoids [4]. Common side effects include mild gastrointestinal complaints like bloating, gas, and temporary changes in bowel habits [6][8]. Serious adverse events are rare but can occur: in one pilot study of FMT enemas for proctitis, 3 of 30 patients had serious events including UC flare (2 patients) and C. difficile colitis (1 patient) [8]. The LOTUS trial reported worsening UC in 2 of 15 FMT patients and 1 of 20 placebo patients [6].

Despite promising results, several challenges remain before FMT becomes a standard UC treatment. First, response is variable — roughly 40–60% of patients respond, and researchers don't yet fully understand why. The STOP-Colitis trial showed that response depends on successful microbial engraftment, which is not guaranteed [1]. Second, the optimal protocol (donor selection, dose, frequency, delivery route) is not standardized. Studies use different donors, some use multiple donors [2], and some use antibiotics before FMT [6][8]. Third, long-term safety data are limited — most trials follow patients for only 8–12 weeks. A 2025 review notes that heterogeneity in protocols and lack of long-term follow-up remain barriers [10]. Finally, practical issues like home storage of frozen capsules and patient adherence need to be addressed [11]. The field is moving toward identifying 'super donors' and developing targeted microbial therapies based on the bacteria that drive response [1][9].

About These Sources

This answer is built on 13 peer-reviewed studies — published from 2020 to 2026, 3 from 2024 or later, 7 in Q1 journals, collectively cited 719 times — selected as the most relevant from 15 studies that passed quality screening, drawn from 45 papers retrieved from a database of over 500 million.

Sources used in this answer

Related research questions